Target intelligence / Profile preview

Cytochrome b-245 chaperone 1 (CYBC1)

Target
CYBC1
Molecular classification
Chaperone protein, Other
01

Overview

Cytochrome b-245 chaperone 1 (CYBC1) is a protein chaperone essential for the formation and stable expression of the CYBA and CYBB subunits of the cytochrome b-245 heterodimer, a core component of the phagocyte NADPH oxidase complex[1][2][4][5][6]. CYBC1 localizes mainly to the endoplasmic reticulum and is required for the proper assembly of the NADPH oxidase complex, which catalyzes the production of reactive oxygen species (ROS) by immune cells during the respiratory burst in response to pathogens[2][6][7][8]. Genetic deficiency of CYBC1 results in a distinctive form of chronic granulomatous disease (CGD5), causing impaired ROS production, susceptibility to life-threatening bacterial and fungal infections, and increased risk of inflammatory bowel disease[1][2][7]. No direct therapeutic drugs target CYBC1 at this time; its clinical significance is largely as a genetic cause of primary immunodeficiency and a diagnostic biomarker for CGD[1][2].

Other names
C17orf62EROSEssential for reactive oxygen species proteinCGD5MGC4368FLJ90469uncharacterized protein C17orf62
02

Biological functions

Innate immune responseRespiratory burst after phagocytosisFormation of the NADPH oxidase complex
03

Disease associations

Primary immunodeficiency (Chronic granulomatous disease, especially autosomal recessive CGD5)Inflammatory bowel diseaseSusceptibility to severe bacterial and fungal infections
04

Safety considerations

Loss of CYBC1 function may cause impaired phagocyte (immune cell) function, leading to severe, recurrent infections and inflammatory bowel disease
05

Biomarkers

Deficiency or mutation used as a diagnostic biomarker for chronic granulomatous disease (CGD)

Beyond the preview

Go deeper on Cytochrome b-245 chaperone 1 (CYBC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome b-245 chaperone 1 (CYBC1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call